Pulse dosing of thioguanine in recalcitrant psoriasis

Archives of Dermatology

Volumn 135, Issue 4, 1999, Pages 433-437

  Silvis, Nancy G ^a   Levine, Norman ^b  

^a Section of Dermatology   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; ETRETINATE; HYDROXYUREA; TIOGUANINE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; LEUKOPENIA; MALE; PRIORITY JOURNAL; PSORIASIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0032932145     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.135.4.433     Document Type: Article

References (17)

1. Adamson PC, Poplack DG, Balls FM. The cytotoxicity of thioguanine mercaptopurine in acute lymphoblastic leukemia. Leuk Res. 1994;18:805-810.
2. Armstrong RD, Vera P, Snyder P. Enhancement of 6-thioguanine cytotoxic activity with methotrexate. Biochem Biophys Res Commun. 1982;109:595-601.
3. Brox LW, Birkett L, Belch A. Clinical pharmacology of oral thioguanine in acute myelogenous leukemia. Cancer Chemother Pharmacol. 1981;6:35-38.
4. Demis DJ, Brown CS, Crosby WH. Thioguanine in the treatment of certain autoimmune, immunologic and related diseases. Am J Med. 1964;37:195-205.
5. Zackheim HS, Maibach HI. Treatment of psoriasis with 6-thioguanine. Semin Dermatol. 1985;4:283-288.
6. Molin L, Thomsen K. Thioguanine treatment in psoriasis. Acta Derm Venereol. 1987;67:85-88.
7. Zackheim HS, Glogau RG, Fisher DA. 6-Thioguanine treatment of psoriasis: experience in 81 patients. J Am Acad Dermatol. 1994;30:452-458.
8. Kao NL, Rosenblate HJ. 6-Thioguanine therapy for psoriasis causing hepatic venoocclusive disease. J Am Acad Dematol. 1993;28:1017-1018.
9. Gill RA, Onstad GR, Cardamone JM, Maneval DC, Sumner HW. Hepatic venoocclusive disease caused by 6-thioguanine. Ann Intern Med. 1982;96:58-60.
10. Satti MD, Weinbren K, Gordon-Smith EC. 6-Thioguanine as a cause of toxic venoocclusive disease of the liver. J Clin Pathol. 1982;35:1086-1091.
11. Nelson JA, Carpenter JW, Rose LM, Adamson DJ. Mechanisms of action of 6-thioguanine, 6-mercaptopurine and 8-azaguanine. Cancer Res. 1975;35:2872-2878.
12. Pan BF, Nelson JA. Characterization of DNA damage in 6-thioguanine-treated cells. Biochem Pharmacol. 1990;40:1063-1069.
13. Gottleib AB. Immunologic mechanisms of psoriasis. J Am Acad Dermatol. 1998; 18:1376-1380.
14. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type I cell-mediated response. Invest Dermatol. 1993;101:701-705.
15. Cadman E, Heimer R, Davis L. Enhanced 5-fluorouracil nucleotide formation alter methotrexate administration: explanation for drug synergism. Science. 1979; 205:1135-1137.
16. Marsh JC, Bertino JR, Katz KH. The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol. 1991;9:371-380.
17. Tan CT, Wollner N, Trippett T. Pharmacologic-guided trial of sequential methotrexate and thioguanine in children with advanced malignancies. J Clin Oncol. 1994;12:1955-1962.